However, the development of antibody‐based targeted therapy is still hindered by limited efficacy resulting from drug resistance (antigen loss), safety concerns, and the uneven presence of a small range of tumor antigens that can be targeted.[2] Human epidermal growth factor receptor 2 (HER2), nectin‐4, trophoblast surface antigen 2 (TROP2), folate receptor alpha (FRα), and tissue factor (TF) have been validated as antibody targets for solid‐tumor therapy.[2, 3] Emerging various tumor targets are also demonstrated to be heterogeneously expressed in tumor tissues. This evidence concerns the gene F3 and neoplasm.